Corona Remedies makes stellar entry on Dalal Street with 38% premium over issue price
N Shorts
Corona Remedies makes stellar entry on Dalal Street with 38% premium over issue price
Corona Remedies made a remarkable debut on the stock market, opening with a significant premium. The company's Rs 655-crore IPO was massively oversubscribed, attracting strong interest from institutional and retail investors alike. This robust demand reflects confidence in Corona Remedies' solid financial performance, strategic focus on key healthcare areas, and promising earnings potential.

Technically enhanced content presented under fair use in public-interest journalism.


Discover more from Newz Quest

Subscribe to get the latest posts sent to your email.

By Vanshika

Meet Vanshika, a promising trainee at Newzquest.in, who plays a vital role in managing the news site’s operations with dedication and precision. With a strong interest in economics and data-driven insights, Vanshika focuses on analyzing economic trends to provide clear and timely news reporting. Her analytical mindset and eagerness to learn have made her an important contributor to the editorial process, enhancing content quality and aligning with the diverse expectations of Newzquest’s audience. Committed to continual growth, Vanshika actively deepens her understanding of the news landscape to offer nuanced insights on critical issues, helping foster a well-informed community.

Translate »

Discover more from Newz Quest

Subscribe now to keep reading and get access to the full archive.

Continue reading